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Abstract
Mucosa-associated lymphoid tissue (MALT) lymphoma is a type of extranodal marginal zone B-cell lymphoma and
is a distinct subtype of non-Hodgkin’s lymphoma.
Primary MALT lymphomas can also occur in the oral cavity, although their appearance in this location is rare. The
neoplastic cells of which MALT lymphomas are composed express B-cell antigens and show monotypic
immunoglobulin expression with light-chain restriction.
Although neoplastic MALT lymphoma cells do not express CD5, previous studies have shown that CD5 positive
MALT lymphomas are more prone to dissemination than those that do not express CD5. Moreover, there are some
reports that describe kappa- and lambda- dual light chain expression in B cell malignant neoplasms.
A 66-year-old Japanese woman with swelling of the right buccal mucosa was referred to our hospital. The lesion
was excised and was pathologically diagnosed as a MALT lymphoma tumor with a t(11;18)(q21;q21) chromosome
translocation.
Swelling of the right buccal mucosa recurred 2 years later. The recurrent tumor was then excised and
pathologically diagnosed as MALT lymphoma.
Immunohistochemical examination of CD5, lambda, and kappa expressions revealed that the primary tumor was
positive for CD5, kappa, and lambda, but the recurrent tumor was weakly positive for CD5 and kappa.
With respect to lambda positivity, the recurrent tumor showed negativity.
Our study suggests that immunohistochemical expression of CD5, kappa, and lambda in oral MALT lymphoma
have the risk of recurrence.
We first described the recurrence of CD5 positive MALT lymphoma in the oral cavity and compared the
immunohistochemical expressions of CD5, lambda, and kappa between the primary and recurrent tumors.
Background
Mucosa-associated lymphoid tissue (MALT) lymphoma is
a type of extranodal marginal zone B-cell lymphoma and
is a distinct subtype of non-Hodgkin’s lymphoma [1].
The most common site of MALT lymphomas is the
stomach, and the majority of gastric MALT lymphomas
are associated with Helicobacter pylori infection [2].
Other sites where MALT lymphomas can occur include
the orbit, lung, salivary glands, thyroid, skin, intestine,
and liver [3]. Salivary gland and thyroid MALT lympho-
mas are associated with autoimmune disorders such as
Sjogren’s syndrome and Hashimoto disease, respectively
[4,5]. Primary MALT lymphomas can also occur in the
oral cavity, although their appearance in this location is
rare [6].
The neoplastic cells of which MALT lymphomas are
composed express B-cell antigens and show monotypic
immunoglobulin expression with light-chain restriction
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express CD5 [8] although some researchers have
reported that CD5 positive MALT lymphomas exist [7].
Furthermore, previous studies have shown that CD5
positive MALT lymphomas are more prone to dissemi-
nation than those that do not express CD5 [9].
Demonstration of light chain restriction in a B lym-
phocyte population is considered proof of monoclonality
and indicates malignancy [10]. Moreover, there are
some reports that describe kappa- and lambda- dual
light chain expression in B cell malignant neoplasms
[10,11].
In oral MALT lymphoma, there are no reports that
investigate immunohistochemical comparison of CD5,
lambda, and kappa expression in primary and recurrent
MALT lymphomas.
We studied the case of a patient with a recurrent CD5
positive MALT lymphoma located in the buccal mucosa
that showed weak, positive expression of CD5 and
kappa and negative expression of lambda.
Case presentation
Clinical presentation
A 66-year-old Japanese woman with swelling of the right
buccal mucosa was referred to our hospital. She was
generally healthy and her medical, dental, and family
histories were normal. Routine laboratory examinations
did not reveal any abnormalities.
The lesion was excised and was pathologically diag-
nosed as a MALT lymphoma tumor with a t(11;18)(q21;
q21) chromosome translocation [12]. Swelling of the
right buccal mucosa recurred 2 years later. Clinical
examination at that time revealed a sessile, hard, elastic,
and movable mass in the right buccal mucosa; similar to
previous clinical findings, this mass was covered with
normal mucosa.
The recurrent tumor was excised under general
anesthesia, and general safety margins were maintained.
The recurrent tumor was similar to the primary tumor;
a sessile, white, elastic, and circumscribed mass. The
recurrent tumor was well demarcated and was covered
with normal mucosa. The length of the recurrent tumor
was 3.3 cm.
To determine whether the lymphoma had spread to
other sites, computed tomography (CT) scans and mag-
netic resonance imaging (MRI) of the whole body were
performed and endoscopic examination of the stomach
was added. All test results were negative for the pre-
sence of lymphoma in the other sites. Clinically, the
patient remained in good general health, and evidence
of tumor reactivation 6 months after the treatment was
lacking.
Microscopic findings
Paraffin sections of the primary tumor revealed (under a
low-power field) some colonized lymphoid follicles with
a mantle zone and diffuse proliferation of tumor cells in
the marginal zone (Figure 1A). On the other hand, par-
affin sections of the recurrent tumor revealed that the
tumor cells showed follicular colonization in the germ-
inal centers throughout the tumor (Figure 2A).
Under high-power fields, small- or medium-sized cen-
trocyte-like cells with indented nuclei and moderate
cytoplasm volume were found in the primary and recur-
rent tumor (Figure 1B and 2B). Monocytoid B-cells with
round nuclei and abundant, pale cytoplasm and neoplas-
tic cells with Dutcher bodies were more abundant in the
primary tumor than in the recurrent tumor (Figure 1B
and 2B).
Figure 1 Light microscopic examination of primary tumor. Low-
power magnification (×50) show some colonized lymphoid follicles
with mantle zone in the primary MALT lymphoma (A). High-power
magnification (×630) show centrocyte-like cells, monocytoid B-cells,
and neoplastic cells which have Dutcher body in the primary MALT
lymphoma (B).
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prevalent in the recurrent tumor than in the primary
tumor (Figure 1B and 2B).
Immunohistochemical findings
For immunohistochemical analyses, paraffin sections
were incubated with primary antibodies, including CD10
(M0727, DAKO, Copenhagen, Denmark), CD20
(M0755, DAKO), CD43 (MT1 clone, Leica Microsys-
tems, UK), CD79a (JCB117 clone, Dakocytomation,
Denmark), Bcl-2 (M0887, DAKO), Bcl-6 (M7211, Dako-
cytomation), IgG (A0423, DAKO), IgG4 (05-3800,
Nichirei-Zymed, Tokyo, Japan), IgM (A0425, Dakocyto-
mation), Lambda (A0193, DAKO), Kappa (A0191,
DAKO), cyclin D1 (SP4 clone, DBIOSYS, Washington
D.C, U.S.A), CK (AE1/3) (M0835, DAKO), and Helico-
bacter pylori (B0471, Dakocytomation).
The sites for antigen-antibody reactions were visua-
lized using a standard avidin-biotinylated-peroxidase
complex method. The primary tumor cells were positive
for bcl-2, CD20, CD43, CD79a, Lambda, Kappa and was
negative for CD10, IgG, IgG4, IgM, cyclin D1, bcl-6, CK
(AE1/3), and Helicobacter pylori (data not shown) [12].
The overall staining results of the recurrent tumor were
similar to those of the initial tumor. The recurrent
tumor showed negativity for CD10, IgG, IgG4, IgM,
cyclin D1, Bcl-6, CK (AE1/3), and Helicobacter pylori
(data not shown) except that the recurrent tumor
showed negativity for lambda and weak positivity for
kappa.
A previous study revealed that MALT lymphomas that
express CD5 tend to recur and disseminate [9]. To
ascertain whether the primary tumor expressed CD5,
the tumor specimen was incubated with a CD5 anti-
body. Moreover, expressions of lambda and kappa in the
primary tumor specimen were compared with those in
the recurrent tumor specimen.
Immunohistochemical examination of CD5, lambda,
and kappa expressions revealed that the primary tumor
was positive for CD5 (Figure 3A), kappa (Figure 3C),
and lambda (Figure 3E), but the recurrent tumor was
weakly positive for CD5 (Figure 3B) and kappa (Figure
3D).
With respect to lambda positivity, the recurrent tumor
showed negativity (Figure 3F).
Discussion
Immunohistochemically, malignant MALT lymphoma
cells express markers of B-cell lineage, but are distinct
from follicular lymphomas (which express CD10), man-
tle cell lymphomas (which express cyclin D1 and CD5),
and small lymphocytic lymphomas (which express CD5
and CD23) [13].
Typically, the neoplastic MALT lymphoma cells coex-
press CD20+ and surface light-chain restriction but are
negative for CD10 and CD5. Some researchers have
documented expression of CD5 in MALT lymphomas,
which is rare. Aberrant CD5-expression is thought to be
a marker of early dissemination and aggressive behavior
in some patients, but CD5 expression in localized, indo-
lent MALT-type lymphomas has been reported [13].
CD5 is a T-cell antigen that is expressed on normal B-
cells, in cord blood, adult peripheral blood, spleen, and
lymph nodes. CD5 is also occasionally expressed on B-
cell neoplasms, but its clinicopathological significance in
low-grade B-cell non-Hodgkin’sl y m p h o m a s( N H L ) ,
notably MALT lymphomas, remains obscure [7]. In the
oral cavity, previous report described that primary
MALT lymphoma with the expression of CD5 occurred
in the tongue [14]. Although MALT lymphoma
expressed CD5, this MALT lymphoma did not recur.
Figure 2 Light microscopic examination of recurrent tumor.
Low-power magnification (×50) show that recurrent tumor cells
formed follicular colonization in the germinal centers throughout
the tumor (A). High-power magnification (×630) show centrocyte-
like cells and plasmacytoid differentiation in the recurrent MALT
lymphoma. Plasmacytoid differentiation was more prevalent in the
recurrent tumor than in the primary tumor (B).
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of MALT lymphoma in buccal mucosa occurred recur-
rence. Whether CD5 expression is relevant to the
p r o g n o s i so fp a t i e n t sw i t hM A L Tl y m p h o m ai sc o n t r o -
versial [9].
Kojima and colleagues reported that MALT lym-
phoma occurred in the soft palate and recurred [6,15].
This MALT lymphoma showed positivity for kappa but
negativity for CD5.
Compared with our primary case and Kojima and col-
leagues’ case, our primary case expressed CD5, kappa-,
and lambda-light chain. The presence of both kappa-
and lambda-light chain-restricted B-cell populations in
B-cell lymphomas, including MALT lymphoma, is an
unusual findings [16].
Edinger et al. reported 2 other examples of primary
cutaneous marginal zone lymphomas that express both
kappa- and lambda-light chain-restricted B-cell popula-
tions [17].
In this study, kappa- and lambda-light chains were
clonally related to each other [16]. Fujiwara et al.
described the aggressive B cell lymphoma with kappa-
and lambda- dual light chain expression [11]. They con-
sidered that kappa- and lambda- dual light chain expres-
sion was involved in the aggressiveness of B cell
lymphoma.
Harby et al. observed that the frequent lambda- light
chain gene rearranged and expressed in murine CD5+ B
lymphoma cells and these lymphoma cells had a func-
tional kappa- chain allele when induced for kappa-
chain expression with bacterial lipopolysaccharide [18].
This mechanism in CD5+ B lymphoma cells may be
related to the recurrence of our case.
Gastric MALT lymphomas are correlated with Helico-
bacter pylori gastritis because colonization of Helicobac-
ter pylori in the gastric mucosa results in lymphoid
infiltration and the formation of acquired lymphoid tis-
sue [19].
Moreover, T cells are specific for Helicobacter pylori
and neoplastic B cells in gastric MALT lymphomas gen-
erate autoantibodies [20].
We considered that the pathogenesis of oral MALT
lymphoma is related to Helicobacter pylori infection;
however, Helicobacter pylori were not detected by
immunohistochemical analysis or endoscopy in either
the primary or the recurrent tumors. These results sug-
gest that oral MALT lymphoma etiology is a result of
several distinct factors and not exclusively Helicobacter
pylori infection.
Although it is well known that MALT lymphomas fre-
quently occur in the background of inflammatory disor-
ders when B cell clones become independent in their
growth [14], the development of oral MALT lymphoma
is largely unknown. Present studies are considering
a l l e r g i e st om e t a l sa n dp e r i o d o n t i t i sa sf a c t o r sf o rt h e
development of MALT lymphoma of the oral cavity.
Therefore, further investigations are necessary to clarify
the mechanism of the development of oral MALT
lymphoma.
Our study suggests that immunohistochemical expres-
sion of CD5, kappa, and lambda in oral MALT lym-
phoma have the risk of recurrence. Our study raises the
possibility to decide the therapeutic strategy whether
oral MALT lymphoma expresses CD5, kappa, and
lambda.
Although the present patient had no recurrence over 6
months after excision of the recurrent tumor, careful
observation is needed, because the clinicopathological
significance of MALT lymphomas with this rare pheno-
type remains obscure [7].
We first described the recurrence of CD5 positive
MALT lymphoma in the oral cavity and compared
the immunohistochemical expressions of CD5,
lambda, and kappa between the primary and recur-
rent tumors.
Figure 3 Immunohistochemical comparison of CD5, lambda,
and kappa expression in primary and recurrent buccal MALT
lymphomas (magnification ×630). Immunohistochemical staining
of primary tumor sections show that the tumor cells are positive for
CD5 (A), kappa (C), and lambda (E). Immunohistochemical staining
of recurrent tumor sections show that the tumor cells are weakly
positive for CD5 (B) and kappa (D) and negative for lambda (F).
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We studied the case of a patient with a recurrent CD5
positive buccal MALT lymphoma in the oral cavity and
compared the immunohistochemical expressions of
CD5, lambda, and kappa between the primary and
recurrent tumors. We first described the recurrence of
CD5, lambda, and kappa positive MALT lymphoma in
the oral cavity and recurrent MALT lymphoma showed
weak positivity for CD5 and kappa and negativity for
lambda.
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